• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

by | Apr 4, 2025 | Uncategorized

Source: CureToday articles Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles. Read More

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

by | Apr 4, 2025 | Uncategorized

Source: CureToday articles CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials. Read More

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

by | Apr 1, 2025 | Uncategorized

Source: CureToday articles Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit. Read More

Depression, anxiety prevalent among adults with lymphoma, multiple myeloma

by | Apr 1, 2025 | Uncategorized

More than half of patients recently diagnosed with lymphoma or myeloma had clinically significant symptoms of anxiety or depression, according to study results.Those symptoms correlated with reduced quality of life.Oreofe O. Odejide, MD, MPH, associate professor of...

Quadruplet Regimen Preferable to Triplets in Multiple Myeloma

by | Mar 27, 2025 | Uncategorized

Source: CureToday articles Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit. Read More

Daratumumab regimen improves survival in transplant-ineligible multiple myeloma

by | Mar 27, 2025 | Uncategorized

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed multiple myeloma, study results showed.The findings, published in Nature Medicine, support quadruplet therapy with subcutaneous daratumumab...
« Older Entries

Recent Content

  • Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review
  • Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review
  • Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis
  • Bortezomib Off-Week Regimen Shows Promise for Reducing Toxicity in Multiple Myeloma
  • Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
  • LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma
  • Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
  • A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma
  • How well do different chatbots respond to multiple myeloma treatment guidelines?
  • Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT